Explore the web, images, videos, news, and more – all in one place.
·
·
1 min read
The lawsuit, filed in federal court Tuesday, accuses Eli Lilly of using outdated data in advertising campaigns.
Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ad campaigns that exaggerate the efficacy of Lilly’s products.
This is a developing story. Check back for updates.
More stories you might be interested in.
Forbes·3 hours agoA chorus of conservative critics, led by billionaire Elon Musk, have slammed “The Odyssey” as “woke” over Christopher Nolan’s casting choices—while Ben Shapiro has hailed it as a “masterpiece.”
Forbes·9 hours agoThe lawsuit, filed in federal court Tuesday, accuses Eli Lilly of using outdated data in advertising campaigns.
Forbes·18 hours agoWith a fleet of more than 80 aircraft, Philippine Airlines operates across the archipelago and 40 international destinations in Asia, North America, Australia and the Middle East. It has been expanding and upgrading its fleet amid a post-pandemic travel rebound.
Forbes·1 day agoFIFA posted a photo of Spain lifting the World Cup trophy to social media—but President Donald Trump, who lingered on stage, appears to be carefully cropped out.
USA TODAY·4 hours agoNovo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.
FOX News·16 hours agoThe DOJ is investigating whether Harvard allowed Chinese donors to create scholarships excluding American students, potentially violating the Civil Rights Act.
Oprah Daily·11 months agoWe talked to two doctors intent on making the neurodegenerative disease obsolete.
Daily Mail·10 months agoIn the largest study of its kind, researchers examined data to better understand how lifestyle factors, such as smoking, and medical history are involved in cancer development.
Reuters·2 hours agoBy Jonathan Stempel NEW YORK, July 21 (Reuters) - Amgen reached a $74 million settlement of a lawsuit accusing the biotechnology company of waiting too long to disclose that it might owe the Internal Revenue Service $10.7 billion for underreporting six years of taxes. A preliminary settlement of the proposed class action was filed late Monday in Manhattan federal court and requires a judge's
Sports Illustrated·6 hours agoJavier Tebas did not hold back with his critique of the FIFA president.
SerpApi.Org